The antibacterial activity of geraniol and its effect in combination with ampicillin, amoxicillin and clarithromycin against Staphylococcus aureus, Escherichia coli and Helicobacter pylori was tested. The minimum inhibitory concentrations (MICs) and combinatory effects of geraniol against the bacteria were assessed by using the modified broth microdilution and checkerboard assay, respectively. The combinatory effect is expressed as fractional inhibitory concentration index (FICI). The MIC of geraniol against S. aureus, E. coli and H. pylori was found to be 11200, 5600, and 7325 µg/mL, respectively. A significant synergistic effect was observed with geraniol and ampicillin against S. aureus with FICI in the range 0.19 to 0.32. Geraniol and ampicillin exhibited a partial synergistic effect against E. coli. A similar effect was observed with geraniol and clarithromycin against S. aureus. A partial synergistic effect was observed with clarithromycin and geraniol against H. pylori with the FICI value in the range 0.86 to 0.89. An additive effect was observed with geraniol and amoxicillin combination against H. pylori. However, the amoxicillin and clarithromycin dose was reduced by thirty-two fold when combined with geraniol against H. pylori. The anti-H. pylori effect of geraniol with clarithromycin and amoxicillin could be of potential interest in the treatment of H. pylori infection and associated ulcers in humans. Further, geraniol, in combination with other antibiotics, has substantial therapeutic potential against S. aureus and E.coli infection.
Staphylococcus aureus infection includes mild to life-threatening diseases. The antimicrobial resistance of S. aureus strains includes precipitous spread of methicillin-resistant S. aureus (MRSA) both in hospitals and community settings [1] . Escherichia coli, the cause of the majority of urinary tract infections (UTIs), has recently become resistant to antibiotics. For example, the extended-spectrum lactamase-producing E. coli strains have emerged as the most prevalent pathogens in the community [2] . The human bacterial infectious agent, Helicobacter pylori, has been identified to play a causative role in peptic ulcer among the bacterial infections of the gastrointestinal system [3] . The emerging resistance of H. pylori to clarithromycin, metronidazole, and amoxicillin restrict their use in the treatment for infection [3, 4] . Antibiotic resistance in H. pylori, S. aureus, and E. coli infections is a major limitation and remains a major public health problem. Therefore, plant extracts with known antimicrobial effects have a great potential to play a role in the treatment. There is growing interest in finding alternative medications from plant sources due to their availability, affordability, and relatively lower side effects compared with conventional medications [5] .
Geraniol, an acyclic monoterpene alcohol, is approved by the United States Food and Drug Administration as a food flavoring agent and presents in its pure form as a colorless oily liquid [6] . Geraniol, when evaluated by a disc diffusion method, was found to exhibit good antimicrobial activity [7] . Antibacterial activity of rosanol (rose oil as active component) was also found against Pseudomonas, Staphylococcus and Escherichia species [8] . A preliminary report in 1999 showed that rosanol, containing 75% of geraniol, possessed promising anti-H. pylori properties; the MIC 50 of 1% geraniol against H. pylori was observed to be 0.53 mg/L [8] .
In order to curb bacterial resistance, combinations of essential oils with antibiotics are of high importance. Geraniol has been tested in combination with chloramphenicol and tetracycline against several Gram-negative bacteria such as E. coli ATCC 25922, Klebsiella pneumoniae ATCC 700603, Proteus mirabilis ATCC 12453, Pseudomonas aeruginosa ATCC 27853, and S. aureus ATCC 29213. Geraniol and chloramphenicol showed significant synergistic effects against all the bacteria, except S. aureus, and reduced the MIC value of chloramphenicol by ten-fold [9] . The available literature reveals that combinations of geraniol with standard antibiotics (amoxicillin, clarithromycin and ampicillin) against H. pylori, S. aureus, and E. coli have not been explored. The present study is designed to evaluate the combination effect of geraniol with other antibiotics against these bacteria. Table 2 . When geraniol was combined with ampicillin against S. aureus, a significant synergistic effect was observed with the FICI ranging from 0.19 to 0.32. The MIC of ampicillin was markedly lowered from 5 µg/mL to 0.3 µg/mL, equivalent to a sixteen-fold reduction when combined with geraniol, giving a FICI value of 0.19. The combination of geraniol and ampicillin exhibited a partial synergistic effect against E. coli (FICI value 0.75 to 1). Geraniol with clarithromycin also showed a partial synergistic effect against S. aureus (FICI range 0.63 to 0.75). Geraniol and clarithromycin combination showed a partial synergistic effect against H. pylori with the FICI ranging from 0.86 to 0.89. The MIC of clarithromycin was lowered from 0.24 µg/mL to 0.0075 µg/mL, a thirty two-fold reduction when combined with geraniol. The amoxicillin and geraniol combination exhibited an additive effect (FICI value 0.95 to 1). The amoxicillin dose was also reduced by thirty two-fold when combined with geraniol against H. pylori.
The growing incidences of multi drug resistance are a threat to the present health care system. At the same time, the discovery of new antimicrobials is also limited. Hence, the combination of antibiotics with essential oils could be a novel approach to overcome these problems [10] . Previously, geraniol was tested against both slime producing methicillin resistant and methicillin sensitive S. aureus (MRSA and MSSA, respectively). The MIC of geraniol against MSSA and MRSA was reported to be 23.4 mg/mL and 5.8 mg/mL, respectively [11] . In the present investigation, the MIC of geraniol against S. aureus was 11.2 mg/mL, which is within the range of the previously reported studies. Geraniol significantly increased the efficacy of ampicillin against S. aureus, but the mechanism behind this synergistic effect is still unclear. There are reports suggesting geraniol's ability to penetrate into the interior of the bacterial cell and subsequently interacting with intracellular sites [12] and this may be the reason for its antibacterial potential against multiple bacteria. Further studies have reported that geraniol potentiated the effect of chloramphenicol by sixteen-fold against Gram-negative bacteria by inhibiting the efflux mechanism [13] . However, geraniol did not potentiate the effect of chloramphenicol against S. aureus in another study [9] . A geraniol and norfloxacin combination showed a synergistic effect against S. aureus with an FICI value of 0.5 [14] .
The MIC value of geraniol against E. coli in this study was 5.6 mg/mL, which suggest that E. coli is more susceptible to geraniol than S. aureus and H. pylori. However, the geraniol and ampicillin combination did not show a synergistic effect against E. coli. The exact mechanism for its antibacterial activity against E. coli is still unclear. However, this study suggests that geraniol has a greater synergistic effect against Gram-positive than Gram-negative organisms when combined with beta-lactam antibiotics. The geraniol and clarithromycin combination was studied against S. aureus and H. pylori, but not against E. coli due to its high MIC value. The clarithromycin dose was reduced by eight-fold and thirty two-fold against S. aureus and H. pylori, respectively, when combined with geraniol. Further, the amoxicillin dose was reduced by thirty two-fold with geraniol combination against H. pylori. In earlier studies, it was reported that geraniol could be a potent inhibitor of the efflux mechanism in bacteria, which is also responsible for multi-drug resistance in bacteria [13] . Geraniol in combination with ciprofloxacin and chloramphenicol, respectively demonstrated significant activity against multi-drug resistant Gramnegative bacteria, probably due to its potent anti-efflux activity [15, 16] . Geraniol's additive and partial synergistic effect with amoxicillin and clarithromycin, respectively, against H. pylori could be due to its potent anti-efflux mechanism. However, further studies are required to validate this claim.
Our current observations suggest that geraniol could be a potential candidate for use along with triple therapy to combat antibiotic resistance and increase the efficacy of treatment of H. pylori induced ulcer patients. At the same time, it could have significant beneficial effect against S. aureus and E. coli infections when combined with other antibiotics. The reduction in the effective dose of antibiotics could be useful in the clinical setting to eliminate their undesired side effects and also prevent the development of antibiotic resistance in bacteria.
Experimental
Drugs and chemicals: Geraniol (98%) was purchased from SigmaAldrich Chemical Co., USA. Amoxicillin, ampicillin and clarithromycin were procured from PI Chemicals, Shanghai.
Microorganisms:
Helicobacter pylori ATCC 43504, purchased from Choice Care, Kuala Lumpur, Malaysia, was sub-cultured in Mueller-Hinton broth (MHB) supplemented with 10% fetal bovine serum (FBS) and incubated at 37°C in an anaerobic jar containing a microaerophilic gas generator pack (Campy GenTM 2.5 L, ThermoScientific, Oxoid Ltd, UK). Staphylococcus aureus ATCC 25923 and Escherichia coli ATCC 25922 were obtained from the stock culture preserved in the International Medical University, Malaysia.
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Determination of MIC and FICI: Broth microdilution and checkerboard assay was performed to determine the MIC and combination effect of antibiotics and geraniol. In brief, both S. aureus and E. coli strains were thawed, inoculated into 10 mL of Tryptic Soy Broth (TSB) and incubated in a shaking incubator for 18 h at 37°C, 120 rpm. The bacterial suspension either for S. aureus or E. coli was adjusted to 0.5 McFarland standard turbidity equivalent to OD 625 ≈ 0.1 [7, 17] . Clarithromycin was dissolved in distilled water to give stock concentrations of 64 and 2400 µg/mL, while stock solutions of ampicillin 40 and 128 µg/mL were solubilized in 0.1 M phosphate buffer, pH 8.0. Geraniol was solubilized in MHB giving stock concentrations of 44800 and 44 µg/mL. Each well of the 96 well plate contained 50 µL of geraniol, 50 µL antibiotics and 100 µL bacterial suspensions, except for controls wells. The plates were incubated at 37°C for 16 h. The 96-well plates were visually checked for turbidity. MIC is defined as the lowest concentration that inhibits growth of the test microorganism [18] . All experiments were performed in triplicates.
The concentration range (3.43 -879 mg/mL) of geraniol obtained from the literature was used to determine the MIC against H. pylori [17] . The antibiotics and geraniol were mixed with DMSO in 1.5 mL micro-centrifuge tubes and serial two-fold dilutions were performed for the respective antibiotics and geraniol. Then the antibiotics and geraniol were pipetted into respective wells according to their diluted concentrations. Each well contained 10 µL of antibiotics, 10 µL of geraniol and 50 µL of H. pylori suspension, 180 µL of MHB-FBS, except for the control wells and antibiotics or geraniol alone wells. The control wells included a sterility control (only MHB-FBS), and a growth control (medium containing solvent and bacteria). The 96-wells plate was incubated for 72 h at 37 o C under microaerophilic conditions for 5 days. Later, 100 µL was taken from the respective wells and cultured on a 5% sheep blood agar plate (Thermo Fisher Scientific, Malaysia) to find the CFU of the respective concentrations. Besides that, the absorbance of each well was measured at 625 nm. The 'combination' effect of the antibiotics and geraniol was determined by using the FICI value employing the following formula [19] 
